Osteoclasts—the innate immune cells of the bone

Osteopenia and periarticular bony erosion are consequences of chronic inflammatory autoimmune disease due to an imbalance of osteoclast activity relative to new bone formation. Osteoclasts, which are specialized as the only bone resorbing cell type, are differentiated from hematopoietic myeloid precursor cells. Inflammatory signals mediated by multiple types of immune cells and cytokines have significant influence over osteoclast differentiation and function through direct effects on osteoclast precursors and indirect effects via osteoblasts and other cells in the bony microenvironment including synovial cells, stromal cells, osteocytes and chondrocytes. Recent studies have demonstrated that osteoclasts themselves express a number of immune receptors and are regulated similarly to macrophages and dendritic cells, closely related cells in the innate immune system. Though we are only beginning to understand the roles of innate immune receptors in osteoclasts, some of these receptors have been shown to be critical regulators of differentiation and function of osteoclasts. Osteoclasts likely function as the innate immune cells of the bone, thus are highly regulated to appropriately respond to stress and inflammatory changes in their microenvironment.

[1]  D. Lacey,et al.  Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.

[2]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[3]  K. Tan-Takeuchi,et al.  Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. , 2003, The Journal of clinical investigation.

[4]  J. Woo,et al.  Suppression of Osteoprotegerin Expression by Prostaglandin E2 Is Crucially Involved in Lipopolysaccharide-Induced Osteoclast Formation1 , 2004, The Journal of Immunology.

[5]  D. G. Walker Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells , 1975, Science.

[6]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[7]  W. Dougall,et al.  RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.

[8]  S. Goldring,et al.  Inflammatory Mediators as Essential Elements in Bone Remodeling , 2003, Calcified Tissue International.

[9]  Matthew J. Silva,et al.  SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts , 2002, Nature Medicine.

[10]  M. Takami,et al.  A Novel Member of the Leukocyte Receptor Complex Regulates Osteoclast Differentiation , 2002, The Journal of experimental medicine.

[11]  A. Keegan,et al.  IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. , 2003, Blood.

[12]  W. Seaman,et al.  CMRF-35-Like Molecule-1, a Novel Mouse Myeloid Receptor, Can Inhibit Osteoclast Formation1 , 2003, The Journal of Immunology.

[13]  C. Ohlsson,et al.  Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. , 1998, The Journal of endocrinology.

[14]  O. Kollet,et al.  The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. , 2007, Annual review of immunology.

[15]  R R Miles,et al.  Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. , 2001, The Journal of biological chemistry.

[16]  Lisa A. Pitcher,et al.  T-cell receptor signal transmission: who gives an ITAM? , 2003, Trends in immunology.

[17]  S. Teitelbaum,et al.  Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.

[18]  T. Nakashima,et al.  Force‐Induced Osteoclast Apoptosis In Vivo Is Accompanied by Elevation in Transforming Growth Factor β and Osteoprotegerin Expression , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  T. Taniguchi,et al.  Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis , 2004, Nature.

[20]  I. Reid,et al.  A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. , 2002, Human molecular genetics.

[21]  H. Takayanagi,et al.  Novel osteoclast signaling mechanisms , 2007, Current osteoporosis reports.

[22]  S. Latour,et al.  Negative regulation of immunoreceptor signaling. , 2002, Annual review of immunology.

[23]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[24]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[25]  D. McVicar,et al.  Functional association of FcepsilonRIgamma with arginine(632) of paired immunoglobulin-like receptor (PIR)-A3 in murine macrophages. , 1999, Blood.

[26]  S. K. Lee,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with , 2022 .

[27]  L. Lanier,et al.  TREM2, a DAP12‐Associated Receptor, Regulates Osteoclast Differentiation and Function , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  H. Kitaura,et al.  Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. , 2003, Bone.

[29]  S. Teitelbaum,et al.  Successful bone-marrow transplantation for infantile malignant osteopetrosis. , 1980, The New England journal of medicine.

[30]  Tak W. Mak,et al.  Autoamplification of NFATc1 expression determines its essential role in bone homeostasis , 2005, The Journal of experimental medicine.

[31]  W. Seaman,et al.  Pattern Recognition by TREM-2: Binding of Anionic Ligands1 , 2003, The Journal of Immunology.

[32]  S. Teitelbaum,et al.  M-CSF mediates TNF-induced inflammatory osteolysis. , 2005, The Journal of clinical investigation.

[33]  T. Björkman,et al.  Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. , 2001, Biochemical and biophysical research communications.

[34]  Leena Peltonen,et al.  Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts , 2000, Nature Genetics.

[35]  S Gordon,et al.  Macrophage receptors and immune recognition. , 2005, Annual review of immunology.

[36]  T. Martin,et al.  Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. , 1998, Endocrinology.

[37]  K. Yudoh,et al.  Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1β and tumour necrosis factor α , 2004 .

[38]  G. Lisignoli,et al.  Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12 , 2003, Histochemistry and Cell Biology.

[39]  C. Abram,et al.  The Expanding Role for ITAM-Based Signaling Pathways in Immune Cells , 2007, Science's STKE.

[40]  L. Hofbauer,et al.  Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.

[41]  G. Trinchieri,et al.  Fc receptor gamma-chain activation via hOSCAR induces survival and maturation of dendritic cells and modulates Toll-like receptor responses. , 2005, Blood.

[42]  R. Baron,et al.  The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice. , 1999, Bone.

[43]  L. Lanier,et al.  Cutting Edge: Inhibition of TLR and FcR Responses in Macrophages by Triggering Receptor Expressed on Myeloid Cells (TREM)-2 and DAP121 , 2006, The Journal of Immunology.

[44]  G D Roodman,et al.  Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. , 1992, The Journal of clinical investigation.

[45]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  L. Hofbauer,et al.  Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. , 2004, JAMA.

[47]  T. Martin,et al.  Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .

[48]  D. Lacey,et al.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.

[49]  L. Hood,et al.  OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. , 1998, Journal of immunology.

[50]  B. Riggs,et al.  Regulation of osteoclastogenesis and RANK expression by TGF‐β1 , 2001 .

[51]  C. Buonsanti,et al.  Impaired Differentiation of Osteoclasts in TREM-2–deficient Individuals , 2003, The Journal of experimental medicine.

[52]  M. Colonna,et al.  The TREM receptor family and signal integration , 2006, Nature Immunology.

[53]  D. McVicar,et al.  Functional Association of FcɛRIγ With Arginine632 of Paired Immunoglobulin-Like Receptor (PIR)-A3 in Murine Macrophages , 1999 .

[54]  R. Kitazawa,et al.  Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. , 2002, Journal of Biological Chemistry.

[55]  L. Lanier,et al.  The Signaling Adapter Protein DAP12 Regulates Multinucleation During Osteoclast Development , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[56]  S. Mumm,et al.  Heritable disorders of the RANKL/OPG/RANK signaling pathway. , 2004, Journal of musculoskeletal & neuronal interactions.

[57]  S. Morony,et al.  TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.

[58]  S. Miller Rapid activation of the medullary bone osteoclast cell surface by parathyroid hormone , 1978, The Journal of cell biology.

[59]  L. Mei,et al.  Regulation of osteoclast function and bone mass by RAGE , 2006, The Journal of experimental medicine.

[60]  R. Kitazawa,et al.  Transforming Growth Factor- (cid:1) Induces Expression of Receptor Activator of NF- (cid:2) B Ligand in Vascular Endothelial Cells Derived from Bone* , 2002 .

[61]  Yongwon Choi,et al.  TRANCE is a TNF family member that regulates dendritic cell and osteoclast function , 1999, Journal of leukocyte biology.

[62]  A. Levine,et al.  Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. , 2005, Endocrinology.

[63]  L. Samelson,et al.  Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. , 2002, Annual review of immunology.

[64]  B. Riggs,et al.  Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. , 1998, Biochemical and biophysical research communications.

[65]  M. Colonna,et al.  Activating and inhibitory functions of DAP12 , 2007, Nature reviews. Immunology.

[66]  W. Dougall,et al.  A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function* , 2002, The Journal of Biological Chemistry.

[67]  S. Yamasaki,et al.  Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. , 2000, Biochemical and biophysical research communications.

[68]  S. Nishikawa,et al.  The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.

[69]  L. Lanier,et al.  Bone Microenvironment Specific Roles of ITAM Adapter Signaling during Bone Remodeling Induced by Acute Estrogen-Deficiency , 2007, PloS one.

[70]  R. Nissenson,et al.  PTH Differentially Regulates Expression of RANKL and OPG , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[71]  T. Taniguchi,et al.  Signaling crosstalk between RANKL and interferons in osteoclast differentiation , 2002, Arthritis research.

[72]  O. Salonen,et al.  CNS manifestations of Nasu–Hakola disease , 2001, Neurology.

[73]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[74]  G. Trinchieri,et al.  OSCAR is an FcRγ-associated receptor that is expressed by myeloid cells and is involved in antigen presentation and activation of human dendritic cells , 2004 .

[75]  D. Lacey,et al.  Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .

[76]  P. Hudler,et al.  Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[77]  J. Penninger,et al.  RANK-L and RANK: T cells, bone loss, and mammalian evolution. , 2002, Annual review of immunology.

[78]  W. Zou,et al.  Syk, c-Src, the αvβ3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption , 2007, The Journal of Cell Biology.

[79]  N. Athanasou,et al.  Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. , 1990, Journal of clinical pathology.

[80]  L. Lanier,et al.  The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. , 2000, Immunology today.

[81]  U. Lerner,et al.  Inhibition of Hormone and Cytokine-stimulated Osteoclastogenesis and Bone Resorption by Interleukin-4 and Interleukin-13 Is Associated with Increased Osteoprotegerin and Decreased RANKL and RANK in a STAT6-dependent Pathway* , 2006, Journal of Biological Chemistry.

[82]  U. Lerner,et al.  Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. , 2002, Bone.

[83]  Ari Elson,et al.  Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells , 2006, Nature Medicine.

[84]  R. Wallace,et al.  Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.

[85]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[86]  F. Hentati,et al.  Nasu-Hakola disease in two Tunisian siblings: new radiological findings , 2000, Neuroradiology.

[87]  K. Takagi,et al.  Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density. , 1999, The American journal of pathology.

[88]  Hiroshi Takayanagi,et al.  Mechanistic insight into osteoclast differentiation in osteoimmunology , 2005, Journal of Molecular Medicine.

[89]  M. Reth Antigen receptor tail clue , 1989, Nature.

[90]  A. Wetterwald,et al.  Role of colony‐stimulating factor‐1 in bone metabolism , 1994, Journal of cellular biochemistry.

[91]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[92]  R. Marcus,et al.  IGF-I Regulates Osteoprotegerin ( OPG ) and Receptor Activator of Nuclear Factor-B Ligand in Vitro and OPG in Vivo , 2002 .

[93]  A. Zallone,et al.  c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. , 2003, The Journal of clinical investigation.

[94]  K. Yudoh,et al.  Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. , 2004, Annals of the rheumatic diseases.

[95]  U. Lerner,et al.  IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-κB Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvariae1 , 2002, The Journal of Immunology.

[96]  L. Lanier,et al.  Inhibition of Immune Responses by ITAM-Bearing Receptors , 2006, Science's STKE.

[97]  S. Akira,et al.  Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis , 2006, Nature Cell Biology.

[98]  L. Lum,et al.  Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. , 1999, The Journal of biological chemistry.

[99]  J. She,et al.  Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. , 2006, Biochemical and biophysical research communications.

[100]  J. Ravetch,et al.  FcR gamma chain deletion results in pleiotrophic effector cell defects. , 1994, Cell.

[101]  L. Lum,et al.  Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, Journal of Biological Chemistry.

[102]  T. Nagy,et al.  The Effect of Class A Scavenger Receptor Deficiency in Bone* , 2007, Journal of Biological Chemistry.

[103]  c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation , 2003 .

[104]  S. Teitelbaum Osteoclasts: what do they do and how do they do it? , 2007, The American journal of pathology.

[105]  S. Akira,et al.  MyD88 But Not TRIF Is Essential for Osteoclastogenesis Induced by Lipopolysaccharide, Diacyl Lipopeptide, and IL-1α , 2004, The Journal of experimental medicine.

[106]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[107]  A. Villa,et al.  Osteopetroses and immunodeficiencies in humans , 2006, Current opinion in allergy and clinical immunology.

[108]  L. Peltonen,et al.  Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. , 2002, American journal of human genetics.

[109]  A. Mócsai,et al.  The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase , 2004 .

[110]  J. Ravetch,et al.  FcR γ chain deletion results in pleiotrophic effector cell defects , 1994, Cell.

[111]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[112]  D L Lacey,et al.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[113]  A. Mócsai,et al.  The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[114]  M. de Vernejoul,et al.  Osteoprotegerin and inflammation. , 2002, European cytokine network.

[115]  Y. Kadono,et al.  Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction , 2006, The Journal of experimental medicine.

[116]  Y. Kadono,et al.  Segregation of TRAF6‐mediated signaling pathways clarifies its role in osteoclastogenesis , 2001, The EMBO journal.

[117]  M. Noda,et al.  Involvement of FcRgamma in signal transduction of osteoclast-associated receptor (OSCAR). , 2004, International immunology.

[118]  D. Lacey,et al.  Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. , 1999, Bone.

[119]  Jude E. Onyia,et al.  Stimulation of Osteoprotegerin (OPG) Gene Expression by Transforming Growth Factor-β (TGF-β) , 2001, The Journal of Biological Chemistry.

[120]  L. Lanier,et al.  Role of ITAM‐containing adapter proteins and their receptors in the immune system and bone , 2005, Immunological reviews.

[121]  S. Reddy,et al.  Characterization of immortalized osteoclast precursors developed from mice transgenic for both bcl-X(L) and simian virus 40 large T antigen. , 1999, Endocrinology.

[122]  T. Martin,et al.  Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction , 2022 .

[123]  Y. Toyama,et al.  DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells , 2005, The Journal of experimental medicine.

[124]  W. Zou,et al.  High dose M‐CSF partially rescues the Dap12−/− osteoclast phenotype , 2003, Journal of cellular biochemistry.

[125]  L. Peltonen,et al.  DAP12/TREM2 Deficiency Results in Impaired Osteoclast Differentiation and Osteoporotic Features , 2003, The Journal of experimental medicine.

[126]  T. Kurosaki,et al.  Paired Immunoglobulin-like Receptor (PIR)-A Is Involved in Activating Mast Cells through Its Association with Fc Receptor γ Chain , 1998, The Journal of experimental medicine.

[127]  L. Piccio,et al.  Cutting Edge: TREM-2 Attenuates Macrophage Activation1 , 2006, The Journal of Immunology.

[128]  P. Maquet,et al.  Nasu-Hakola syndrome: polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia. , 1997, Journal of medical genetics.

[129]  T. Watts,et al.  TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.

[130]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[131]  L. Lanier,et al.  Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12 , 2005, Nature Immunology.